Vanda Pharmaceuticals Reports 18% Revenue Growth to $56.3 Million in Q3 2025

Vanda Pharmaceuticals Inc. reported a total revenue of $56.3 million for the third quarter of 2025, marking an 18% increase from $47.7 million in the same period last year. The growth was primarily driven by a 31% rise in net product sales of Fanapt®, which reached $31.2 million, up from $23.9 million in the prior year. However, the company experienced a slight increase in HETLIOZ® sales, which rose to $18.0 million, and a 20% increase in PONVORY® sales, totaling $7.0 million. Despite the revenue growth, Vanda reported a net loss of $22.6 million for the quarter, compared to a loss of $5.3 million in the same quarter of 2024.

For the nine months ending September 30, 2025, Vanda's total revenues increased by 9% to $158.9 million, up from $145.6 million in the same period of 2024. Fanapt® sales contributed significantly to this growth, with a 24% increase to $84.1 million. In contrast, HETLIOZ® and PONVORY® sales saw declines of 3% and 7%, respectively. The company's operating expenses surged to $269.7 million, up from $176.0 million in the previous year, largely due to increased research and development costs and heightened selling, general, and administrative expenses associated with the commercial launches of Fanapt® and PONVORY®.

Vanda's strategic developments included the ongoing commercialization of its products and the expansion of its clinical pipeline. The company is actively pursuing regulatory approvals for several products, including Bysanti™ and tradipitant, with target action dates set for early 2026. Additionally, Vanda has initiated a direct-to-consumer campaign to enhance brand awareness and has expanded its sales force to support its commercial activities. The company also reported a collaborative framework with the FDA to expedite reviews of certain applications, which may positively impact future product launches.

Operationally, Vanda's total cash and cash equivalents, along with marketable securities, decreased to $293.8 million as of September 30, 2025, down from $374.6 million at the end of 2024. The company reported a net cash used in operating activities of $80.0 million for the nine months ended September 30, 2025, a significant increase from $13.9 million in the same period last year. This increase was attributed to a higher net loss and changes in operating assets and liabilities. Vanda's employee headcount has also increased as part of its expansion efforts, reflecting its commitment to enhancing its commercial infrastructure.

Looking ahead, Vanda Pharmaceuticals anticipates fluctuations in its financial performance due to various factors, including the success of its product launches, ongoing clinical trials, and potential regulatory approvals. The company remains focused on addressing high unmet medical needs through its innovative therapies while navigating the challenges posed by market conditions and competition.